Evidence map›Paper›PMID 24769644›Full record

Trial reportBlood cancer journal2014

The optimal use of PEG-asparaginase in relapsed ALL--lessons from the ALLR3 Clinical Trial.

A Masurekar, C Fong, A Hussein, T Revesz, P M Hoogerbrugge, S Love, C Ciria, C Parker, S Krishnan, V Saha

Abstract readLetterMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Blood cancer journal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Activity and toxicity of intramuscular 1000 iu/mBritish journal of haematology · 2022
    Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

A MasurekarChildren's Cancer Group, Manchester Academic Health Sciences Centre, Institute of Cancer, University of Manchester, Manchester, UK.
C FongChildren's Cancer Group, Manchester Academic Health Sciences Centre, Institute of Cancer, University of Manchester, Manchester, UK.
A HusseinChildren's Cancer Group, Manchester Academic Health Sciences Centre, Institute of Cancer, University of Manchester, Manchester, UK.
T ReveszDepartment of Haematology-Oncology, SA Pathology at Women's and Children's Hospital and University of Adelaide, Adelaide, South Australia, Australia.
P M Hoogerbrugge1] Childrens Hospital, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands [2] Dutch 17 Childhood Oncology Group, The Hague, The Netherlands.
S LoveCentre for Statistics in Medicine, University of Oxford, Oxford, UK.
C CiriaCentre for Statistics in Medicine, University of Oxford, Oxford, UK.
C ParkerChildren's Cancer Group, Manchester Academic Health Sciences Centre, Institute of Cancer, University of Manchester, Manchester, UK.
S Krishnan1] Children's Cancer Group, Manchester Academic Health Sciences Centre, Institute of Cancer, University of Manchester, Manchester, UK [2] Department of Paediatric Oncology, Tata Translational Cancer Research Centre, Kolkata, India.
V Saha1] Children's Cancer Group, Manchester Academic Health Sciences Centre, Institute of Cancer, University of Manchester, Manchester, UK [2] Department of Paediatric Oncology, Tata Translational Cancer Research Centre, Kolkata, India.

Funding

Cancer Research UK 14840Cancer Research UK 16895Cancer Research UK A6791Cancer Research UK A9394
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdolescentAsparaginaseChildFemaleHumansMalePolyethylene GlycolsPrecursor Cell Lymphoblastic Leukemia-LymphomaAsparaginasepegaspargasePolyethylene Glycols

Identifiers

PMID24769644
PMCPMC4003420

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.